Conformis Ranked Number One in Patent Power Among Medical Device Companies
Honor recognizes strength and impact of Conformis’ broad and expanding patent portfolio for technology related to company’s customized orthopedic implants and instruments
Bedford, Mass. – December 1, 2014 – Conformis, Inc., a medical device company providing the only truly customized total knee implant system for patients, today announced that Conformis ranked at the top of the Patent Power 2014 Scorecard for medical equipment and instrument companies. The annual ranking was published in the IEEE Spectrum, a publication of the Institute of Electrical and Electronics Engineers. The rankings are based on the patent portfolios of more than 6,000 leading commercial enterprises, academic institutions, nonprofit organizations, and government agencies worldwide. This benchmarking—carried out by 1790 Analytics, based in Haddonfield, N.J.—takes into account not only the size of an organization’s patent portfolios but also the quality, as reflected in characteristics such as growth, impact, originality, and general applicability.
“We are proud to have developed innovative, customized orthopedic implant solutions, the first truly game-changing technology in the field for quite some time. Our ranking is a reflection of our ongoing commitment to provide revolutionary solutions for superior patient outcomes. We started with customized knee replacements, but our platform technology is broadly applicable to multiple areas of individualized medicine,” said Philipp Lang, MD, MBA, Chairman and CEO of Conformis. “We are especially pleased to be named among so many global technology leaders such as Apple, Microsoft, IBM, 3M, and Google, who were also named as top-ranked in patent strength in their sectors.”
Conformis is the first and only company to market a fully customized knee implant for patients who need total or partial knee replacement. The company’s proprietary production process and technology platform use a CT scan of each patient’s knee to design and manufacture a customized knee implant and a full suite of single-use, pre-sterilized instruments for use in only that patient. Patents awarded to Conformis in recent years cover patient-specific implants, instruments, software and manufacturing processes in multiple orthopedic fields.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that is pioneering a patient-specific approach to orthopedic implants and instrumentation. Its proprietary technology is supported by more than 400 patents and patent applications. Conformis’ award winning partial and total knee replacement solutions, the iUni® G2, iDuo® G2 and iTotal® G2, are individually designed for each patient. Potential advantages compared to traditional off-the-shelf implants include faster recovery, shorter hospital stay, less blood loss, more bone preservation, and better functional outcomes with more natural feeling knees. Conformis products are provided in a pre-sterilized single package delivery system that can help hospitals reduce costs and treat more patients by reducing instrument re-sterilization costs and shortening set-up, procedure and turnover times. The iUni® G2, iDuo® G2 and iTotal® G2, have been cleared by the U.S. FDA and are CE Marked in Europe.
Conformis is the leader in additive manufacturing in the orthopedic and medical device space. Conformis is the only orthopedic company that offers Just-In-Time (JIT) manufacturing with a single-package delivery system, resulting in greatly enhanced use of working capital.
Conformis technology is broadly applicable to all joints. The company is expanding into new applications and indications.
90% Patient Satisfaction Reported in Peer-Reviewed Clinical Study of Conformis iTotal PS Knee Replacements
Clinical research published online in July 2020 in The Journal of Bone and Joint Surgery Reviews found that the patients
Conformis Announces 510(k) Clearance for iTotal® Identity PS
iTotal® Identity PS joins iTotal® Identity CR as the latest personalized knee technology from Conformis BILLERICA, Mass., June 22, 2020 (GLOBE NEWSWIRE)